Skip to main content
. Author manuscript; available in PMC: 2016 Jul 15.
Published in final edited form as: Behav Brain Res. 2015 Apr 9;288:54–62. doi: 10.1016/j.bbr.2015.04.002

Fig. 1.

Fig. 1

Effects of systemic physostigmine on immobility time in the FST and on total locomotor activity. A. Experimental timeline for the FST, including a 15 min pretest 24 hr prior to the FST test session. B. Administration of physostigmine led to increased immobility time in FST (p < 0.05, main effect of drug; p < 0.05, Tukey post-hoc for 0.125 mg/kg physostigmine versus saline). C. Systemic physostigmine administration did not alter locomotor activity as measured by locomotor photobeam breaks (p > 0.05, two-way repeated measures ANOVA).